PCSK9 and androgen insensitivity syndrome: Given recent preclinical studies on PCSK9-mediated T cell differentiation, we first assessed the effects of the PCSK9 inhibitor evolocumab on peripheral blood T lymphocyte subsets in patients with AIS in this analysis.